Endo, GlaxoSmithKline announce senior management changes
Endo has hired a new chief operating officer, while GlaxoSmithKline has announced a succession plan for its vaccines business.
Two area drug companies announced changes to their management teams on Friday.
Endo Pharmaceuticals Holdings Inc. hired Julie McHugh as chief operating officer of the Chadds Ford company. Most recently, McHugh had been president and CEO of Nora Therapeutics, a venture-backed start-up.
But before that McHugh had been president of Centocor Inc., the Horsham-based biotech firm owned by Johnson & Johnson.
Endo president and CEO David Holveck also ran Centocor, prior to McHugh, when it was acquired by J&J in 1999.
GlaxoSmithKline P.L.C. unveiled a succession plan for its vaccines business, which is based in Rixensart, Belgium, and has a manufacturing plant in Marietta, Lancaster County.
Jean Stephenne was named chairman of GSK Biologicals, adding the title to his current responsibilities as president.
The pharmaceutical company, which employs several thousand in the Philadelphia region including at its Upper Merion research complex, said that operations of the business unit will be transitioned to Moncef Slaoui over the next two years. Slaoui has been chairman of research and development since June 2006.